The Roche’s ‘Avastin’ is domestically approved for the indication of cervical cancer

Published: 2015-03-26 14:03:49

Updated: 2015-03-26 14:18:24

The indication of the targeted agent, ‘Avastin’, has domestically been approved.

Thus, Avastin (bevacizumab) is now able to jointly use either taxane-type (paclitaxel) and platinum-type (cisplatin) drugs or paclitaxel and topotecan targeting durable, recurrent and metastatic cervical cancer patients.

Currently, the cervical cancer treatment guideline of the National Comprehensive Cancer Netwo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.